PU-H71 HCl (Zelavespib HCl) is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. PU-H71 HCL shows antitumor activity in many preclinical models of malignancy. PU-H71 HCL has an inhibitory effect on the protein expression levels of Rad51 and Ku70, which may be associated with the double chain break repair in the homologous recombination pathway and non-homologous end-joining pathway.

Zoledronic Acid (ZOL 446) is a bisphosphonate. Zoledronic Acid (ZOL 446) is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronic Acid (ZOL 446) is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.

Human PTHrP-(1-34)NH2, also known as PTH-Related Protein (1-34) amide for human, mouse, and rat, is the N-terminal fragment of PTHrP. This peptide induces hypercalcemia and is utilized in the study of humoral hypercalcemia of malignancy [1].

ABBV-467, a selective MCL-1 inhibitor (K i : <0.01 nM), induces apoptosis and effectively promotes cancer cell death while inhibiting tumor growth in hematological malignancy models, including multiple myeloma [1].

Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.

Lacto-N-fucopentaose II (LNFP II), a sialyl-Lewis hapten of the human Lewis blood group determinant, serves as a monosialo-ganglioside/glycolipid and sialyl derivative, CA 19-9. It is recognized as a molecular tumor marker (TM) for biliopancreatic malignancy [1].

Anzurstobart (CC-95251; BMS-986351), a fully human monoclonal anti-SIRPα antibody with high affinity, inhibits CD47-SIRPα interaction. It potentiates macrophage-mediated phagocytosis of DLBCL cell lines in co-culture assays with Rituximab and shows promise in solid and hematologic malignancy research [1].

PU-H54 is a purine-based inhibitor of Grp94. It is a Grp94-selective resorcinol-based inhibitor isolated through probing of the exclusive binding region of S2 subpocket in Grp94.

N1,N8-Diacetylspermidine is a polyamine found in human urine.N1,N8-Diacetylspermidine can be used as a marker for cancer and malignancy.

Human PTHrP-(1-36) is a secreted form of parathyroid hormone-related protein that exhibits anticalciuric effects and promotes beta cell function and proliferation. It is utilized in research pertaining to humoral hypercalcemia of malignancy (HHM) and hyperparathyroidism [1] [3].

PI3Kδ/γ-IN-2 is a potent, orally bioavailable dual inhibitor of PI3Kδ (IC50: 1 nM) and PI3Kγ (IC50: 4.3 nM) with potential for use in anti-B-cell malignancy studies.

ND-2110, a selective interleukin-1 receptor-associated kinase 4 inhibitors, is used for the treatment of autoimmune disorders and lymphoid malignancy.

TNO155 is a protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11) inhibitor(IC50 : 0.011 µM),with potential antineoplastic activity.

AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs. AZD-9574 exhibits anti-cancer activities and can be used in studies about HRD+ breast cancer and advanced solid malignancies.

SPC-180002, a dual SIRT1/3 inhibitor, exhibits IC50 values of 1.13 and 5.41 μM for SIRT1 and SIRT3, respectively. It disrupts redox homeostasis through ROS generation, consequently enhancing p21 protein stability and inducing mitochondrial dysfunction. Furthermore, this compound significantly impedes cell cycle progression and malignancy proliferation, while also activating the Nrf2 signaling pathway [1].

SOR-C13 TFA, a truncated carboxy-terminal peptide, serves as a potent TRPV6 antagonist, demonstrating high affinity with an IC 50 value of 14 nM. TRPV6, a non-voltage-gated calcium channel linked to malignancy and poor prognosis in breast cancer, is effectively targeted by SOR-C13 TFA, indicating its anticancer activity [1].

DS69910557, a potent, selective, and orally active antagonist of the human parathyroid hormone receptor 1 (hPTHR1), exhibits antagonistic activity with an IC50 value of 0.08 μM. It is useful in researching hyperparathyroidism, hypercalcemia of malignancy, and osteoporosis.

PI3Kδ-IN-11 is a potent and selective PI3Kδ inhibitor (IC50: 27.5 nM) that dose-dependently blocks PI3K/Akt pathway activity. PI3Kδ-IN-11 can be used in B- or T-cell-associated malignancy studies.

Suberoyl bis-hydroxamic acid (SBHA) is a Histone deacetylase (HDAC) inhibitor. HDAC is required for transcriptional modulation, cell cycle regulation and development. It is an enzyme that deacetylates lysine residues on the N-terminal of the core histones.

AZ5576 is a potent and highly selective CDK9 inhibitor. AZ5576 can be used for the research of Hematological Malignancy [1].

(Rac)-Lisaftoclax ((Rac)-APG-2575), a Bcl-2 inhibitor, is utilized in hematologic malignancy research (CN112898295A) [1].

PLS-123 is a novel covalent irreversible Btk inhibitor with potential anti-proliferative activity. PLS-123 exhibited more potent anti-proliferative effects than ibrutinib in multiple cellular and in vivo preclinical models of B-cell lineage malignancy, including 14 kinds of cell lines, patients’ primary tumor cells and mouse xenograft model.

Physcion 8-O-β-D-glucopyranoside (Physcion 8-O-beta-D-monoglucoside) has anti-inflammatory and anti-cancer activities. Physcion 8-O-β-D-glucopyranoside can be used in studies about common malignancy cancer.

KUSC-5001 is a potent inhibitor (IC50: 18 μM) of HIF-1, which has a key role in tumour survival and malignancy.